Loading…
In the context of Fecal Microbiota Transplantation (FMT) & Alcoholic hepatitis, the transferability of ethanol-induced liver diseases was demonstrated in preclinical models using the Fecal Microbiota Transplantation (FMT) (1)
A meta-analysis consisted of six studies conducted in India (2, 3, 5, 6, 7, 8) with a total of 371 patients with severe alcoholic hepatitis (SAH) revealed that FMT has promising short-term benefits for survival rates at 1- and 3-month post-treatment. However, no significant difference was observed between the FMT-treated and SOC-treated groups at 6 and 12 months. Further future research is needed to identify strategies for optimizing long-term treatment efficacy (4).
Fecal Microbiota Transplantation (FMT) has also resulted in improved survival in patients with severe alcoholic hepatitis (1).
The randomized open-label clinical treatment trial NCT03091010 - Fecal Microbiota Transplantation (FMT) vs Prednisolone & Alcoholic hepatitis revealed that Fecal Microbiota Transplantation (FMT) is safe. It improves 90-day survival, reduces infections, and modulates microbial communities favorably. It can be an alternative to prednisolone therapy (3)
The open-label non-randomized treatment trial NCT03827772 - Fecal Microbiota Transplantation (FMT) & Alcoholic hepatitis revealed that Fecal Microbiota Transplantation (FMT) is safe, improves short-term and medium-term survival, and leads to improvement in clinical severity scores in patients with severe alcoholic hepatitis (SAH) presenting as acute-on-chronic liver failure (ACLF) (2)
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
see also:
Alcoholic hepatitis & Drugs/Treatments
Fecal Microbiota Transplantation (FMT) & Liver Fibrosis / Cirrhosis
Fecal Microbiota Transplantation (FMT) (procedure-based) & Preclinical/Clinical data